Trelavue 50mg. 600mg. 300mg Tablet
PDF Leaflet Revision Date: 21 April 2016
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents.
Dosage (summary)
One tablet once daily for adults and adolescents over 40 kg.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding due to potential teratogenicity.
Key Drug Interactions
- Dofetilide
- Pilsicainide
- Metformin
- Antacids containing polyvalent cations
Contraindications
- Hypersensitivity to components
- Moderate and severe hepatic impairment
- Creatinine clearance < 50 ml/min
Common side effects
- Hypersensitivity reactions
- Nausea
- Diarrhoea
- Fatigue
- Rash
Counselling Points
- Inform about hypersensitivity risks and symptoms.
- Never restart TRELAVUE after hypersensitivity.
- Monitor for signs of lactic acidosis.
- Avoid breastfeeding while on TRELAVUE.
Serious warnings
- Severe hypersensitivity reactions
- Lactic acidosis
- Osteonecrosis
- Pancreatitis
Important Disclaimer
The Trelavue 50mg. 600mg. 300mg Tablet professional information leaflet below is the property of Gsk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
